Citations 34

Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium

Alzheimer's & Dementia | February 24, 2022 | Volume: 18 | Issue: 9 | Pages: 1677-1686

10.1002/alz.12589 | PMID 35199931

AbstractThe Alzheimer's Association hosted the second Latinos & Alzheimer's Symposium in May 2021. Due to the COVID‐19 pandemic, the meeting was held online over 2 days, with virtual presentations, discussions, mentoring sessions, and posters. The Latino population in the United States is projected to have the steepest increase in Alzheimer's disease (AD) in the next 40 years, compared to other ethnic groups. Latinos have increased risk for AD and other dementias, limited access to quality care, and are severely underrepresented in AD and dementia research and clinical trials. The symposium highlighted developments in AD research with Latino populations, including advances in AD biomarkers, and novel cognitive assessments for Spanish‐speaking populations, as well as the need to effectively recruit and retain Latinos in clinical research, and how best to deliver health‐care services and to aid caregivers of Latinos living with AD.
The screening and enrollment of underrepresented ethnoracial and educational populations in the Alzheimer's Disease Neuroimaging Initiative

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S10 | Pages: No page available

10.1002/alz.057424

AbstractBackgroundAn analysis of the ethnoracial and educational composition of Alzheimer's Disease Neuroimaging Initiative (ADNI) participants, and the relationship between ethnoracial/education and screening, enrollment, dropout, and biomarkers is needed to assess the generalizability of ADNI data to diverse populations, and to inform efforts to increase diversity.MethodData from all 4 ADNI phases were used to determine ethnoracial and educational breakdown and differences of the following ADNI participation metrics: screening, screen fails, enrollment, as well as drop‐out within and between ADNI phases. Multivariable logistic regression was used to analyze the association between ethnoracial and educational group and either amyloid positivity or ApoE e4 status, adjusting for age, gender, and diagnostic group.ResultAcross the 4 ADNI phases (screened: n=3,739; enrolled: n=2,286), 11% of screened and enrolled participants identified as Latinx, non‐Latinx Black, or non‐Latinx‐Asian and 16% of the screened and 15% of the enrolled participants reported having =<12 years of education. In contrast, the 2019 US Census American Community Survey for adults 60+ reports 25% non‐White, and 44 % =< 12 years of education. There were no observed differences between participants from historically underrepresented ethnoracial groups and NLW participants in screen fail and dropout rates. We found that individuals with =<12 years of education failed screening at a significantly higher rate (p=.01) and rolled‐over significantly less to subsequent ADNI phases (p<.001) compared to individuals with an education >12 years. Identifying as non‐Latinx Asian was associated with lower odds of being amyloid positive (OR=0.36; p=.014) and an ApoE4 carrier (OR=0.36; p=.008) compared to NLW. Identifying as Latinx was associated with being less likely to be amyloid positive than NLW participants (OR=0.54; p=.031).ConclusionCompared to the US Census, ADNI underrepresents enrollment of Latinx, non‐Latinx Black, and non‐Latinx Asian participants and those with low educational attainment. Hence, ADNI reflects the on‐going challenges with recruiting and enrolling underrepresented populations into most AD research. Our findings highlight the need for ADNI to increase enrollment and engagement of underrepresented ethnoracial and educational populations. ADNI is actively undertaking steps to implement improved recruitment approaches aimed at increasing ethnoracial and socioeconomical representation in multi‐center cohort studies.
Abstract T P74: Mild Stroke in a Telemedicine Network: Identification, Treatment, and Outcomes

Stroke | July 3, 2021 | Volume: 46 | Issue: suppl_1 | Pages: No page available

10.1161/str.46.suppl_1.tp74

Introduction: "Mild" stroke is not well defined, but is a relative contraindication for the administration of IV rtPA. Advances in telemedicine have allowed for specialized practitioners to observe the examination, rather than rely on the on-scene examiner. We investigated whether there were differences in rates of identification, treatment, and outcomes of mild stroke patients in the phone compared to the video arms of a telestroke network. Methods: The STRokE DOC trials were prospective, randomized, outcome-blinded trials comparing video telemedicine to phone-only evaluations, which assessed eligibility for IV rtPA and correctness of decision-making for 2 hubs and 6 spokes. This analysis included all adult acute ischemic stroke patients from the STRokE DOC trials who were defined as “mild” using a recent definition from the TREAT Task Force. Rates of ICH, mortality, and dichotomized 90-day mRS scores were compared between the video and phone arms. Results: Mild stroke accounted for 32% and 29% of the video and phone arms, respectively. The two groups had similar baseline characteristics except hypertension (higher rate in video arm). Of the video mild stroke patients, 13% had poor outcome (mRS>1) compared to 24% of the phone arm (p=0.45). There were no symptomatic ICH or deaths. Among IV rtPA treated mild stroke patients, all of the video arm had good outcome, versus 25% of the phone arm. Of 100 non-treated patients, 34 were excluded because of "too mild" a deficit (TMT). In the phone arm, 7 of these did not meet the TREAT-derived criteria for mild stroke (p=0.03). One TMT patient in the phone arm had poor outcome. Conclusions: Mild stroke made up a third of the patients in each group. Some TMT patients in the phone arm did not meet the criteria for mild stroke; their subtle findings may not have been conveyed adequately over the phone. Among IV rtPA treated patients, the phone arm had worse outcomes. The results raise concern regarding accuracy of predicting outcomes for mild stroke patients, especially when based on a phone description. The study numbers were small, so conclusions cannot be definitively made. Future studies are necessary to determine decision making factors within the telemedicine process that influence treatment outcomes among mild stroke patients.
The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression

Journal of Alzheimer’s Disease | March 2, 2021 | Volume: 80 | Issue: 3 | Pages: 991-1002

10.3233/jad-201089 | PMID 33682706

Background: Cognitive impairment (CI) is a key feature of late life depression (LLD), but the contribution of underlying neurodegenerative pathology remains unclear. Objective: To evaluate cognitive dysfunction in LLD relative to a sample of nondepressed (ND) older adults with matched levels of memory impairment and amyloid-β (Aβ) burden. Methods: Participants included 120 LLD and 240 ND older adults matched on age, education, sex, Mini-Mental State Exam, mild cognitive impairment diagnosis, and PET Aβ burden. Results: LLD showed higher rates of impairment relative to ND with 54.6% of the LLD sample demonstrating impairment in at least one cognitive domain compared to 42.9% of controls ( H = 7.13, p = 0.008). LLD had poorer performance and higher rates of impairment on Rey Auditory Verbal Learning Test learning and memory compared to controls. In the overall sample, Aβ positivity was associated with worse performance on Logical Memory I ( p = 0.044), Logical Memory II ( p = 0.011), and Trail Making Test –B ( p = 0.032), and APOE ɛ4 genotype was associated with worse performance on Logical Memory I ( p = 0.022); these relationships did not differ between LLD and ND. Conclusion: LLD showed higher rates of CI driven by focal deficits in verbal learning and memory. Alzheimer’s disease (AD) biomarkers were associated with worse performance on timed set-shifting and story learning and memory, and these relationships were not impacted by depression status. These findings suggest that AD may account for a portion of previously reported multi-domain CI in LLD and highlight the potential for AD to confound studies of cognition in LLD.
P4‐321: TAU PET IN A4: PRELIMINARY REPORT

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_30 | Pages: No page available

10.1016/j.jalz.2018.07.144

F3‐02‐02: MODELING LONG‐TERM DISEASE PROGRESSION WITH COVARIATES

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2014.04.253

Estimating long‐term multivariate progression from short‐term data

Alzheimer's & Dementia | March 22, 2014 | Volume: 10 | Issue: 5S | Pages: No page available

10.1016/j.jalz.2013.10.003 | PMID 24656849

AbstractMotivationDiseases that progress slowly are often studied by observing cohorts at different stages of disease for short periods of time. The Alzheimer's Disease Neuroimaging Initiative (ADNI) follows elders with various degrees of cognitive impairment, from normal to impaired. The study includes a rich panel of novel cognitive tests, biomarkers, and brain images collected every 6 months for as long as 6 years. The relative timing of the observations with respect to disease pathology is unknown. We propose a general semiparametric model and iterative estimation procedure to estimate simultaneously the pathological timing and long‐term growth curves. The resulting estimates of long‐term progression are fine‐tuned using cognitive trajectories derived from the long‐term “Personnes Agées Quid” study.ResultsWe demonstrate with simulations that the method can recover long‐term disease trends from short‐term observations. The method also estimates temporal ordering of individuals with respect to disease pathology, providing subject‐specific prognostic estimates of the time until onset of symptoms. When the method is applied to ADNI data, the estimated growth curves are in general agreement with prevailing theories of the Alzheimer's disease cascade. Other data sets with common outcome measures can be combined using the proposed algorithm.AvailabilitySoftware to fit the model and reproduce results with the statistical software R is available as the grace package. ADNI data can be downloaded from the Laboratory of NeuroImaging.
CT Interpretation in a Telestroke Network

Stroke | September 15, 2012 | Volume: 43 | Issue: 11 | Pages: 3095-3097

10.1161/strokeaha.112.666255 | PMID 22984007

Background and Purpose— The American Stroke Association guidelines emphasized the need for further high-quality studies that assess agreement by radiologists and nonradiologists engaged in emergency telestroke assessments and decision-making. Therefore, the objective of this study was to determine the level of agreement of baseline brain CT scan interpretations of patients with acute stroke presenting to telestroke spoke hospitals between central reading committee neuroradiologists and each of 2 groups, spoke hospital radiologists and hub hospital vascular neurologists (telestrokologists). Methods— The Stroke Team Remote Evaluation Using a Digital Observation Camera Arizona trial was a prospective, urban single-hub, rural 2-spoke, randomized, blinded, controlled trial of a 2-way, site-independent, audiovisual telemedicine and teleradiology system designed for remote evaluation of adult patients with acute stroke versus telephone consultation to assess eligibility for treatment with intravenous thrombolysis. In the telemedicine arm, the subjects’ CT scans were interpreted by the hub telestrokologist and in the telephone arm by the spoke radiologist. All subjects’ CT scans were subsequently interpreted centrally, independently, and blindly by 2 hub neuroradiologists. The primary CT outcome was determination of a CT-based contraindication to thrombolytic treatment. Kappa statistics and exact agreement rates were used to analyze interobserver agreement. Results— Fifty-four subjects underwent random assignment. The overall agreement for the presence of radiological contraindications to thrombolysis was excellent (0.91) and did not differ substantially between the hub telestrokologist to neuroradiologist and spoke radiologist to neuroradiologist (0.92 and 0.89, respectively). Conclusions— In the context of a telestroke network designed to assess patients with acute stroke syndromes, agreement over the presence or absence of radiological contraindications to thrombolysis was excellent whether the comparisons were between a telestrokologist and neuroradiologist or between spoke radiologist and neuroradiologist. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00623350.
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics

Neurology | May 13, 2012 | Volume: 58 | Issue: 9 | Pages: 1418-1422

10.1212/wnl.58.9.1418 | PMID 12011296

Efficacy of Telemedicine for Stroke: Pooled Analysis of the Stroke Team Remote Evaluation Using a Digital Observation Camera (STRokE DOC) and STRokE DOC Arizona Telestroke Trials

Telemedicine and e-Health | March 8, 2012 | Volume: 18 | Issue: 3 | Pages: 230-237

10.1089/tmj.2011.0116 | PMID 22400970